TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03489018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study: NCT03308591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACT
Description: Platin based chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RT+PLND
Description: radical hysterectomy+pelvic lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RT+PLND
Description: radical hysterectomy+pelvic lymphadenectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Platin based chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Platin based chemotherapy
Study: NCT05500638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
Study: NCT04065451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine in the submucosal injection fluid
Study: NCT01095978

Intervention type: DRUG
Intervention: Clarithromycin (Klacid SR)
Description: Klacid SR in a dose of 1000 mg once daily
Study: NCT04502225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt
Description: Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated trunk
Description: Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilt - In home
Description: Tilt of the whole bed so that the head is elevated by 8 inches overnight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated Trunk - In home
Description: Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
Study: NCT02287285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin9
Description: Dosed at 600 pmol/kg/min for 210 minutes.
Study: NCT02342197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: half the dose of Gn agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: half the dose of Gn agonist
Study: NCT02578121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4.0 mg will be given on days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
Study: NCT04236921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DopaSnap®
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DopaSnap®
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DopaSnap®
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DopaSnap®
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RDL of CD-LD
Description: (immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
Study: NCT02301156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally
Study: NCT04195880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions to Reduce Acute Care Transfers
Description: Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
Study: NCT04075617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic habit reminder
Description: Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: palatal crib
Description: Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
Study: NCT01512446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per week
Study: NCT04183582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well
Study: NCT01657266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-155
Description: Pre-medication (before surgery) and maintenance treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: Pre-medication (before surgery) and maintenance treatment.
Study: NCT03629652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-down position treatment
Description: In the head-down position, the body is in the supine position with the head lowered to 30 degrees

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Rehabilitation
Description: The body is in the supine position without lowered head

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: The body is in the supine position without lowered head
Study: NCT04366726

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Description: Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
Study: NCT00457639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholic Acid
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholic Acid
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
Study: NCT02733783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold dry air machine
Description: Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
Study: NCT03666884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS 50% eye drops 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AS 50% eye drops 8*1
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
Study: NCT03944044

Intervention type: OTHER
Group type: OTHER
Intervention: Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol
Description: Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.

Intervention type: OTHER
Group type: OTHER
Intervention: Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol
Description: Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
Study: NCT03557216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
Study: NCT02929225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable Capsules
Description: BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo is also prescribed as a dose of 4 capsules twice daily
Study: NCT01395654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid, rifampin, pyrazinamide
Description: rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
Study: NCT03323580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDFT
Description: Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
Study: NCT01183013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone Capsules 30 mg once daily for up to 84 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 45 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
Study: NCT03323580

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: traditional fluid therapy
Description: Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
Study: NCT03760263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
Study: NCT01222143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVE-HiDAC
Description: NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10.
Study: NCT03585101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir
Description: Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
Study: NCT01606696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Higher intensity interval training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intensity non-interval training
Description: Standard intensity non-interval training.
Study: NCT03399162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB Workshop
Description: PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREHAB Workshop
Description: PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREHAB Exercise Program
Description: An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
Study: NCT01655602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure upper edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure lower edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichophytic closure both edge trimming
Description: 'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
Study: NCT03557216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical and occult blood test
Description: A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical and occult blood test
Description: A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin test
Description: Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin test
Description: Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
Study: NCT03015610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: commercially available lansoprazole
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
Study: NCT04025411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Simulation 3 (IVS3) device
Description: Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Mirror Therapy (TM)
Description: Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
Study: NCT01183013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 30 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5mg
Description: Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg / Pioglitazone 15 mg FDC
Description: Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Study: NCT04025411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
Study: NCT01436877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of Temporary Implantable Nitinol Device (TIND)
Description: Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
Study: NCT04434469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7297089
Description: RO7297089 will be given via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7297089
Description: RO7297089 will be given via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7297089
Description: RO7297089 will be given via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7297089
Description: RO7297089 will be given via intravenous (IV) infusion
Study: NCT00254800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel; exenatide
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel; exenatide
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol and levonorgestrel; exenatide
Description: Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
Study: NCT02825758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZestiVits
Description: The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation.
Study: NCT02295020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment only
Description: Standard treatment such as NSAIDs and injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment only
Description: Standard treatment such as NSAIDs and injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard treatment plus Bioskin Ten-7 knee brace
Description: Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.